Answers are grounded in this paper and cite their sources.
Oligodendrocytes, the myelinating cells of the central nervous system, insulate axons with myelin, enabling rapid signal transmission, supporting neuronal metabolism, and contributing to brain plasticity. However, aging and neurodegenerative diseases can significantly impair oligodendrocyte function and myelin integrity. During aging, oligodendrocyte progenitor cells (OPCs) exhibit a reduced regenerative capacity, leading to progressive myelin deterioration and cognitive decline. In Alzheimer’s disease, these age-related myelin deficits are exacerbated by neuroinflammation, oxidative stress, and amyloid-beta (Aβ) and tau pathology, which collectively impair oligodendrocyte survival and remyelination capacity. Similarly, in Parkinson’s disease, α-synuclein aggregation contributes to myelin decline through both shared and disease-specific mechanisms. Here, we highlight key features of aged and diseased oligodendrocytes and myelin pathology, emphasizing their roles in energy metabolism, plasticity, and resilience. Understanding these aspects is essential for developing strategies to counteract myelin deterioration and promote neuroprotection in aging and neurodegenerative diseases.
No takes yet. Share an insight, caveat, or question.
Rojas et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: